A PHASE Ib MULTICENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY EFFICACY AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Colorectal Cancer
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically confirmed adenocarcinoma originating from the colon or rectum 2) Metastatic disease (Stage IV American Joint Committee on Cancer, Version 7) not amenable to local treatment - to ensure that patients are appropriately staged, patients are required to undergo radiological imaging (computed tomography [CT] scan and/or magnetic resonance imaging [MRI]) of the chest, abdomen, pelvis, and brain during screening to document the presence of mCRC that is measurable per RECIST v1.1. 3) Tumors that have high CEACAM5 expression as determined by qRT-PCR in a newly obtained biopsy sample and documented through central testing of a representative tumor tissue specimen performed at baseline
You may not be eligible for this study if the following are true:
-
1) Symptomatic, untreated, or actively progressing CNS metastases 2) Uncontrolled tumor-related pain 3) History of PML 4) History of leptomeningeal disease
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.